INTRODUCTION
With roughly 30% of all people living with HIV globally remaining undiagnosed, innovative HIV testing approaches are essential for meeting the first of the UNAIDS "90-90-90" targets and achieving the benefits of treatment as prevention. 1 HIV self-testing (HIVST) is increasingly being recognized as an HIV testing approach that may appeal to hardto-reach or high-risk individuals who would benefit from frequent HIV testing. 2 Based on research showing high acceptability and interest in HIVST across a wide range of populations and settings, [3] [4] [5] [6] [7] [8] the WHO issued guidelines in December 2016 to support implementation and scale-up evidence-based HIVST approaches. 9 Several countries in subSaharan Africa (SSA), including Kenya, have included HIVST in their testing guidelines and are currently developing plans to implement HIVST. 9, 10 Governments and donors are now exploring HIVST distribution strategies-including retail distribution-that are best suited to enhance HIV testing access among those who are not reached by existing HIV testing services (HTS).
Although self-test kits may become available in private sector pharmacies and other retail outlets, the extent to which they must be subsidized remains unknown. High prices in the retail sector may impede access in target populations, but very low prices or free distribution would require larger public subsidies and potentially misallocate resources by targeting those who already seek existing HTS. There have been few studies that have assessed individuals' willingness to pay (WTP) for self-tests in SSA. Recent agreements between foundations and self-test manufacturers to achieve prices below current levels underscore the need for WTP data. To inform pricing policies for self-tests, we assessed WTP for selftests among Kenyan women participating in a randomized trial.
METHODS
Data were collected as part of a randomized trial to evaluate whether secondary distribution of self-tests can promote partner and couples testing (ClinicalTrials.gov NCT02386215). 11 Participants were 18-39-year-old women recruited between June 11, 2015 and January 16, 2016 from antenatal and postpartum clinics in 3 urban and periurban health centers in Kisumu, Kenya. Participants were randomized to either an HIVST group that received 2 HIV self-tests free-of-charge or to a comparison group that received invitation cards for the male partner to come for clinicbased HIV testing. Self-tests given to participants in the HIVST group were oral fluid-based HIV test kits (OraQuick Rapid HIV-1/2 antibody tests; OraSure Technologies, Bethlehem, PA).
At the time of enrollment, participants were administered a baseline questionnaire that collected information on socioeconomic characteristics and health-related behaviors. Follow-up surveys were conducted with participants at 3 months to learn whether participants' primary partner had an HIV test and whether the couple tested together. The follow-up survey also asked participants in the HIVST group whether they would be willing to pay for HIV self-tests, and if yes, what amount of money they would be willing to pay.
The primary outcome in this substudy was a binary indicator of whether participants were willing to pay a nonzero amount for self-tests (ie, WTP . 0). We made the conservative assumption that participants who reported that they were "not sure if they would pay for a selftest" had WTP = 0. The secondary outcome was the amount, in Kenyan Shillings (KSH), that participants were willing to pay for self-tests. We assumed that participants who were willing to pay something but reported either "don't know" for the WTP amount or refused to answer had a WTP equal to the median value among those with a WTP . 0. Various baseline characteristics of participants were used in our analyses. Categorical variables measured at baseline included educational attainment, occupation, self-reported chance of acquiring HIV in the future, and partner's HIV testing history in the past year. Participants' age, monthly income, and number of times tested for HIV in the past year were measured as continuous variables. Participants' marital status, condom use at last sex, and intimate partner violence history in the year before were classified as binary variables.
Statistical Analyses
We used a modified Poisson regression model to identify predictors of whether participants had a WTP . 0 for self-tests 12 and an ordinary least squares linear regression to identify predictors of the amount that participants were willing to pay for HIV self-tests. All models included robust The study was funded by the International Initiative for Impact Evaluation (TW2-02-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This is an open-access article distributed under the terms of the Creative Commons AttributionNon Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. 
RESULTS
In total, 297 participants were randomized to the HIVST group, and 284 (96%) successfully completed a follow-up interview and provided responses to WTP questions. Four participants (1%) stated that they were "not sure if they would pay for a self-test" and were assigned a WTP = 0. In addition, 23 participants (8%) who were willing to pay something but reported either "don't know" for the WTP amount or refused to answer altogether had a WTP equal to the median value among those with a WTP . 0. A vast majority (250/284, 88%) reported that they would be willing to pay some amount of money for a self-test (Table 1) . The median WTP amount among all participants was 100 KSH (interquartile range 50-150 KSH) or US $1 (interquartile range US $0.50-1.50). Participants with WTP = 0 and WTP . 0 had largely similar characteristics. Because participants were either pregnant or had recently delivered, most participants did not report any earnings in the past month. All participants who self-reported that they had a high chance of acquiring HIV reported that they were willing to pay for a self-test, whereas among those who reported a low chance or no chance, 16% (23/147) reported no WTP.
In regression analyses, the only variable significantly associated with WTP was participants' self-reported chance of acquiring HIV at baseline. Those who reported a high chance were more likely to have a WTP . 0 than those who reported a low chance (risk ratio 1.21; 95% confidence interval: 1.02 to 1.44). There were no differences in WTP amounts, however, between participants with high and low self-reported chances of acquiring HIV. Participants who had tested more often in the past had significantly lower WTP, with each additional HIV test in the past 12 months being associated with a decrease of 16.3 KSH ($0.16) in WTP amount (P = 0.001).
DISCUSSION
Women who sought antenatal and postpartum services in the study and had gained experience using oral fluid-based self-tests reported being willing to pay some money for self-tests in the future. This suggests that self-test kits need not be fully subsidized to achieve reasonable levels of uptake. At the same time, participants' WTP amounts indicated that demand will decline substantially if prices exceed US $1. Strengths of this study include its ascertainment of WTP from individuals who had a chance to become familiar with the new technologies and its focus on oral fluid-based test kits that are likely to become available for retail distribution. These findings could be relevant as the market for HIV self-tests takes shape, with donor agencies and governments making decisions on how much to subsidize the prices for these diagnostic products. This study also helps predict the distributional implications of alternative HIVST pricing policies. Participants' income and other socioeconomic characteristics were not strong predictors of WTP, but rather participants' selfassessed risk of acquiring HIV proved to be more relevant. Importantly, those who perceived themselves to be at high risk were more likely to be willing to pay some amount than those who were at low risk. Those who tested frequently in the past also had lower WTP. From an access standpoint, the findings from this study suggest that charging some money for self-tests may not exclude women at high risk or women with low utilization of existing HTS. The higher demand for self-tests in these groups may be due to both the financial barriers associated with clinic-based services and the greater convenience and privacy of self-tests.
Although self-tests are not currently available for retail distribution in many countries, prices for oral fluidbased self-tests in most low-and middleincome countries have exceeded US $7.50, 13 an amount that few participants in our study were willing to pay. The recent decision by the Bill and Melinda Gates Foundation to subsidize OraQuick test kits and lower their price to US $2 in priority countries in SSA is an important advance in this regard. 14 Based on our findings, however, a price of US $2 may be above the WTP for many individuals. Additional subsidy from governments or greater economies of scale in production may be necessary to ensure high uptake.
This study has several limitations. First, WTP was assessed among women who received free self-tests and gained experience using them. Because familiarity with HIVST is low in much of SSA, WTP in the general population may be lower than it was in women who participated in this study and thus became familiar with self-tests. Supportive evidence stems from a recent study in coastal Kenya, in which uptake of the oral self-tests was low among some pharmacy clients who were offered self-tests for US $1. 15 Based on our study, the WTP amount of US $1 could be viewed as an upper bound of prices that should be charged in urban and periurban areas of Kenya where the study took place. Relatedly, it is likely that WTP will be lower in low-income, rural populations. However, these findings may not generalize to other countries or even other parts of Kenya, where similar assessments of WTP will be necessary to gauge demand. Finally, WTP was self-reported by participants and thus may not be the same as their true WTP. The associations we found are nonetheless useful for identifying segments of the population that have higher demand for self-tests.
The pricing of diagnostic and preventive health products in poor countries is a topic that has received considerable attention in recent years. Several studies conducted in countries like Kenya and Zambia have used field-based pricing experiments in which prices are randomized to individuals to rapidly determine the demand for preventive inputs like antimalarial bednets and water filters. 16, 17 These studies have generally found a decline in demand with higher prices, suggesting that free distribution may be optimal. In some cases, however, small user fees have been rationalized as a way to increase revenue and reduce unnecessary use. Although these products are very different from diagnostics such as HIV self-tests, methods used to estimate demand for these products can be used to further explore the implications of alternative pricing strategies for self-tests. Additional studies exploring demand and WTP in different populations and settings are essential as countries seek to determine optimal subsidy levels for self-tests.
Positive or Not, That Is the Question: HIV Testing for Individuals on Pre-exposure Prophylaxis
To the Editors:
We report a case of an individual exposed to HIV around the time of preexposure prophylaxis (PrEP) initiation where detection of HIV-1 RNA and initial diagnosis were delayed. PrEP has the potential to alter the detection of biomarkers of early and acute infection leading to potential confusion in interpretation of HIV status and delayed treatment of similar cases in settings where PrEP is delivered.
A 31-year-old man presented to a New York City Department of Health clinic for PrEP assessment. A third generation rapid HIV and pooled nucleic acid amplification tests were negative at that time. Seven days later, the patient was seen in the HIV Prevention Program Clinic based in the community and affiliated with New York Presbyterian Hospital-Columbia Medical Center and reported multiple male sexual partners including known HIV-positive partners in the last 3 months and inconsistent condom use. The patient was started on tenofovir-emtricitabine at this visit and was given a 30-day supply. A fourth generation HIV test (Abbott Architect Ag/Ab Combo), gonorrhea and chlamydia from 3 sites, syphilis, and hepatitis (A, B, C) were negative.
Twenty-eight days later, the patient returned to the clinic, reporting 100% tenofovir-emtricitabine adherence. At that time, Abbott HIV Ag/Ab was reactive with a signal-to-cutoff ratio (s/co) of 1.03 (Reactive .1.0). Supplemental testing was performed with the Geenius HIV1/2 Confirmatory Assay (Geenius; Bio-Rad, Marne la Coquette, France) and was negative (Fig. 1) . A qualitative HIV-1 RNA test was sent to the New York State DOH (NYSDOH). These results prompted retesting 4 days later at which point the Abbott Combo s/ co was 0.95, interpreted as "negative," as was a qualitative DNA/RNA PCR (COBAS-Qualitative, AmpliPrep/TaqMan HIV-1 Qual Test). The virus was detected, however, using a quantitative test, COBAS AmpliPrep/TaqMan HIV-1 Test kit, with HIV-1 RNA level below the lower limit of detection (,20 copies/ mL). At this point, Dolutegravir was added to the regimen.
HIV testing was repeated 2 weeks later. Abbott Combo was reactive (s/co = 1.3), Geenius was indeterminate (positive for gp41 only), and COBASQuantitative was not detected. However, COBAS-Qualitative was positive. The initial qualitative HIV-1 RNA from day 28 after PrEP initiation ultimately returned positive. The patient was switched to a once-daily fixed-dose combination antiretroviral regimen and continues to have an undetectable HIV-1 RNA level. A GenoSure archive (GenoSure; Monogram Biosciences, San Francisco, CA) returned with insufficient HIV-infected cells or cellassociated DNA targets to amplify the virus for assessment of mutations.
PrEP is an important tool in efforts to end the HIV epidemic. Recommendations for PrEP care include HIV testing every 3 months. The current Centers for Disease Control (CDC) HIV-testing algorithm recommends an initial fourth generation HIV Antigen/Antibody (Ag/Ab) combination immunoassay, followed by HIV 1/2 differentiation immunoassay if positive and a nucleic acid amplification test if the immunoassay is indeterminate or inconclusive. 1 To date, a comprehensive evaluation of how PrEP could impact diagnosis of acute and early HIV infection has not been fully completed. It also remains to be determined what are optimal ways of discussing and counseling patients about HIV status and timing of infection while on PrEP.
The Fiebig stage classification system is used to characterize the progression from exposure to HIV through HIV seroconversion and uses HIV-1 RNA, p24 antigen, third generation enzyme immunoassay, second generation EIA, and Western Blot to categorize acute and early HIV infection into 6 stages. 2 Typically, in acute HIV, viral RNA levels peak at over 10 5 copies per milliliter at 7-10 days, falling 2-3 log during seroconversion, and before reaching a steady state in 30-50 days. 3 Newer HIV diagnostic assays take advantage of the p24 positivity that occurs with the rise in viral load seen in stage II and early HIV antibodies seen in stage III. These assays have improved sensitivity for detection of early infection and shorten the interval between the time of infection and initial immunoassay reactivity. Their performance in the context of PrEP, however, remains to be determined.
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